Biodegradable gelatin microparticles as delivery systems for the controlled release of bone morphogenetic protein-2.

This work evaluated gelatin microparticles and biodegradable composite scaffolds for the controlled release of bone morphogenetic protein-2 (BMP-2) in vitro and in vivo. Gelatin crosslinking (10 and 40mM glutaraldehyde), BMP-2 dose (6 and 60ng BMP-2 per mg dry microparticles), buffer type (phosphate buffered saline (PBS) and collagenase-containing PBS), and gelatin type (acidic and basic) were investigated for their effects on BMP-2 release. Release profiles were also observed using poly(lactic-co-glycolic acid) (PLGA) microparticles with varying molecular weights (8300 and 57,500). In vitro and in vivo studies were conducted using radiolabeled BMP-2; the chloramine-T method was preferred over Bolton-Hunter reagent for radioiodination with this system. BMP-2 release from PLGA microparticles resulted in a moderate burst release followed by minimal cumulative release, while BMP-2 release from gelatin microparticles exhibited minimal burst release followed by linear release kinetics in vitro. Growth factor dose had a small effect on its normalized release kinetics probably because of an equilibrium between gelatin-bound and unbound BMP-2. Differences in release from acidic and basic gelatin microparticles may result from the different pretreatment conditions used for gelatin synthesis. The in vitro release kinetics for both gelatin microparticles alone and within composite scaffolds were dependent largely on the extent of gelatin crosslinking; varying buffer type served to confirm that controlled release relies on enzymatic degradation of the gelatin for controlled release. Finally, in vivo studies with composite scaffolds exhibited minimal burst and linear release up to 28 days. In summary, dose effects on BMP-2 release were found to be minimal while varying gelatin type and release medium can alter release kinetics. These results demonstrate that a systematic control of BMP-2 delivery from gelatin microparticles can be achieved by altering the extent of basic gelatin crosslinking.

[1]  J. Lane,et al.  Current understanding of osteoconduction in bone regeneration. , 1998, Clinical orthopaedics and related research.

[2]  David L. Kaplan,et al.  BMP-silk composite matrices heal critically sized femoral defects. , 2007, Bone.

[3]  Antonios G Mikos,et al.  In vitro degradation of porous poly(propylene fumarate)/poly(DL-lactic-co-glycolic acid) composite scaffolds. , 2005, Biomaterials.

[4]  K E Healy,et al.  Ectopic bone formation via rhBMP-2 delivery from porous bioabsorbable polymer scaffolds. , 1998, Journal of biomedical materials research.

[5]  Antonios G Mikos,et al.  In vitro release of transforming growth factor-beta 1 from gelatin microparticles encapsulated in biodegradable, injectable oligo(poly(ethylene glycol) fumarate) hydrogels. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[6]  P. Deluca,et al.  Porous bone morphogenetic protein-2 microspheres: Polymer binding and in vitro release , 2001, AAPS PharmSciTech.

[7]  S. Chueh,et al.  Collagen-hydroxyapatite microspheres as carriers for bone morphogenic protein-4. , 2003, Artificial organs.

[8]  P. Deluca,et al.  Effect of a freeze-dried CMC/PLGA microsphere matrix of rhBMP-2 on bone healing , 2001, AAPS PharmSciTech.

[9]  Y. Tabata,et al.  Repairing of rabbit skull defect by dehydrothermally crosslinked collagen sponges incorporating transforming growth factor beta1. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[10]  Y. Ikada,et al.  Controlled release of growth factors based on biodegradation of gelatin hydrogel , 2001, Journal of biomaterials science. Polymer edition.

[11]  R. Mehta,et al.  Interaction of recombinant human bone morphogenetic protein-2 with poly(d,l lactide-co-glycolide) microspheres. , 1996, Pharmaceutical development and technology.

[12]  K. Takaoka,et al.  Repair of a proximal femoral bone defect in dogs using a porous surfaced prosthesis in combination with recombinant BMP-2 and a synthetic polymer carrier. , 2003, Biomaterials.

[13]  G. Lewis.  Alternative acrylic bone cement formulations for cemented arthroplasties: present status, key issues, and future prospects. , 2008, Journal of biomedical materials research. Part B, Applied biomaterials.

[14]  Antonios G Mikos,et al.  Transforming growth factor-beta 1 release from oligo(poly(ethylene glycol) fumarate) hydrogels in conditions that model the cartilage wound healing environment. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[15]  K. An,et al.  Mechanical properties of a biodegradable bone regeneration scaffold. , 2000, Journal of biomechanical engineering.

[16]  Antonios G Mikos,et al.  rhBMP-2 Release from Injectable Poly(DL-Lactic-co-glycolic Acid)/Calcium-Phosphate Cement Composites , 2003, The Journal of bone and joint surgery. American volume.

[17]  Kazutoshi Nozaki,et al.  A biodegradable polymer as a cytokine delivery system for inducing bone formation , 2001, Nature Biotechnology.

[18]  J. Jansen,et al.  Effect of varied release kinetics of the osteogenic thrombin peptide TP508 from biodegradable, polymeric scaffolds on bone formation in vivo. , 2005, Journal of biomedical materials research. Part A.

[19]  W. Parks.  Matrix metalloproteinases in repair , 1999, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[20]  J. Jansen,et al.  In vivo degradation of porous poly(propylene fumarate)/poly(DL-lactic-co-glycolic acid) composite scaffolds. , 2005, Biomaterials.

[21]  Antonios G Mikos,et al.  Gelatin as a delivery vehicle for the controlled release of bioactive molecules. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[22]  H. Burchardt.  The biology of bone graft repair. , 1983, Clinical orthopaedics and related research.

[23]  W. Friess,et al.  Collagen sponges for bone regeneration with rhBMP-2. , 2003, Advanced drug delivery reviews.

[24]  K. Ishihara,et al.  Bone morphogenetic protein encapsulated with a biodegradable and biocompatible polymer. , 1996, Journal of biomedical materials research.

[25]  K E Healy,et al.  Engineering bone regeneration with bioabsorbable scaffolds with novel microarchitecture. , 1999, Tissue engineering.

[26]  A. Mikos,et al.  Crosslinking characteristics of and cell adhesion to an injectable poly(propylene fumarate-co-ethylene glycol) hydrogel using a water-soluble crosslinking system. , 2003, Tissue engineering.

[27]  M. Bostrom,et al.  Expression of bone morphogenetic proteins in fracture healing. , 1998, Clinical orthopaedics and related research.

[28]  Y. Ikada,et al.  Biodegradation of hydrogel carrier incorporating fibroblast growth factor. , 1999, Tissue engineering.

[29]  J. Hassell,et al.  Extracellular matrix : a practical approach , 1995 .

[30]  J. Fisher,et al.  Soft and hard tissue response to photocrosslinked poly(propylene fumarate) scaffolds in a rabbit model. , 2002, Journal of biomedical materials research.

[31]  M Kellomäki,et al.  Bioabsorbable scaffolds for guided bone regeneration and generation. , 2000, Biomaterials.

[32]  Antonios G. Mikos,et al.  In Vitro and In Vivo Release of Vascular Endothelial Growth Factor from Gelatin Microparticles and Biodegradable Composite Scaffolds , 2008, Pharmaceutical Research.

[33]  Zarana S. Patel.  Controlled delivery of angiogenic and osteogenic growth factors for bone regeneration , 2008 .

[34]  Ikada,et al.  Protein release from gelatin matrices. , 1998, Advanced drug delivery reviews.

[35]  M. Kohno,et al.  Distribution and Characterization of Specific Cellular Binding Proteins for Bone Morphogenetic Protein-2 (*) , 1995, The Journal of Biological Chemistry.

[36]  F. Greenwood,et al.  THE PREPARATION OF I-131-LABELLED HUMAN GROWTH HORMONE OF HIGH SPECIFIC RADIOACTIVITY. , 1963, The Biochemical journal.

[37]  Y. Tabata,et al.  Controlled release by biodegradable hydrogels enhances the ectopic bone formation of bone morphogenetic protein. , 2003, Biomaterials.

[38]  Antonios G Mikos,et al.  Dual growth factor delivery from degradable oligo(poly(ethylene glycol) fumarate) hydrogel scaffolds for cartilage tissue engineering. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[39]  M. Wiemann,et al.  The Binding of rhBMP‐2 to the Receptors of viable MC3T3‐E1 Cells and the Question of Cooperativity , 2001 .

[40]  J A Schrier,et al.  Recombinant human bone morphogenetic protein-2 binding and incorporation in PLGA microsphere delivery systems. , 1999, Pharmaceutical development and technology.

[41]  D J Mooney,et al.  Development of biocompatible synthetic extracellular matrices for tissue engineering. , 1998, Trends in biotechnology.

[42]  J. Wozney,et al.  rhBMP‐Collagen Sponges as Osteoinductive Devices: Effects of in Vitro Sponge Characteristics and Protein pI on in Vivo rhBMP Pharmacokinetics , 1999, Annals of the New York Academy of Sciences.

[43]  N. Lang,et al.  Effect of bioresorbable fibres (Polyfibre) and a bioresorbable foam (Polyfoam) on new bone formation. A short term experimental study on the rabbit skull. , 2003, Clinical oral implants research.

[44]  W. Hunter,et al.  The labelling of proteins to high specific radioactivities by conjugation to a 125I-containing acylating agent. , 1973, The Biochemical journal.

[45]  Thomas A Einhorn,et al.  Fracture healing as a post‐natal developmental process: Molecular, spatial, and temporal aspects of its regulation , 2003, Journal of cellular biochemistry.